Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up of MAL Cream for Actinic Keratosis
NCT04269395Phase 3Terminated
- Sponsor
- Galderma
- Start
- Apr 2020
- Primary completion
- Sep 2021
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in actinic keratosis (AK) comparing MAL Cream Arm with Vehicle Cream Arm (2 arms). Primary endpoint: Number of Participants With Recurrence of Any Cleared Treated AK Lesions at Week 54. Started Apr 2020; status: terminated.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT04269395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04269395.